NCT05388669 2026-04-13PALOMA-3Janssen Research & Development, LLCPhase 3 Active not recruiting418 enrolled 16 charts 1 FDA
NCT05663866 2026-04-13Premedication to Reduce Amivantamab Associated Infusion Related ReactionsJanssen Research & Development, LLCPhase 2 Active not recruiting68 enrolled 12 charts
NCT04988295 2026-02-05MARIPOSA-2Janssen Research & Development, LLCPhase 3 Active not recruiting776 enrolled 13 charts 3 FDA
NCT04487080 2026-02-04MARIPOSAJanssen Research & Development, LLCPhase 3 Active not recruiting1,074 enrolled 13 charts 3 FDA